Previous 10 | Next 10 |
Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX ), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform,...
Gainers : BioXcel Therapeutics (NASDAQ: BTAI ) +58% . More news on: BioXcel Therapeutics, Inc., Genprex, Inc., ImmunoGen, Inc., Stocks on the move, , Read more ...
BioXcel Therapeutics (NASDAQ: BTAI ) +67% . More news on: BioXcel Therapeutics, Inc., Canopy Growth Corporation, Blink Charging Co., Stocks on the move, , Read more ...
Gainers: CounterPath (NASDAQ: CPAH ) +32% . More news on: CounterPath Corporation, Genprex, Inc., Happiness Biotech Group Limited, Stocks on the move, , Read more ...
Gainers : Rexahn Pharmaceuticals (NASDAQ: REXN ) +85% . More news on: Rexahn Pharmaceuticals, Inc., Sprint Corporation, Genprex, Inc., Stocks on the move, , Read more ...
Nano cap Genprex ( GNPX +28.6% ) is up on more than double normal volume in reaction to its agreement with the University of Pittsburgh for exclusive rights to a gene therapy for the potential cure of type 1 and type 2 diabetes. More news on: Genprex, Inc., Healthcare stocks news, Stoc...
Sprint (NYSE: S ) +74% after judge approves T-Mobile merger . More news on: Sprint Corporation, Rexahn Pharmaceuticals, Inc., ZK International Group Co., Ltd., Stocks on the move, Read more ...
February 11, 2020 Palm Beach, FL –February 11, 2020 – The global diabetes drugs market size was valued at USD $48,753.1 Million in 2018, is projected to reach USD 78,261.7 Million by the end of 2026, exhibiting a CAGR of 6.1%, according to industry reports. Rise in obesi...
Company licenses patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh Results from in vivo animal studies indicate that normal glucose levels in the blood may be restored for an extended period of time Company plans to partner for t...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its February 4, 2020 receipt of notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the ...
News, Short Squeeze, Breakout and More Instantly...
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Suppor...
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors PR Newswire Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 13, 2024 /PRNews...
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner PR Newswire Ryan Confer Appointed Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" o...